Updated hourlyHourly refreshWed, Oct 28, 2026
Finance · Healthcare
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Rajiv Patni, M.D., as Chief Medical Officer. Dr. Patni is a physician-scientist and accomplished biopharmaceutical executive with more than 25 years of experience leading research, development, regulatory, and medical affairs organizations.
Aug 25 · 12:00·GlobeNewswire
Healthcare · Education
Filament Health's patented, naturally derived psilocybin drug candidate PEX010 will be supplied to an investigator initiated Phase 2a study evaluating a group retreat model of psilocybin therapy in people living with metastatic solid tumors or incurable hematologic malignancies.Toronto, Ontario--(August 25, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within...
Aug 25 · 11:20·Newsfile
AI · Healthcare
“AI can make bioprinting more precise, predictive and personalized, accelerating its path from research to clinical use.”
Aug 25 · 08:52·GlobeNewswire
Healthcare
FORM 8.5 (EPT/RI)
Aug 25 · 08:31·GlobeNewswire
Finance · Healthcare
NEW DELHI, August 25, 2026--IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and biosciences — released new research examining how GLP-1 use is influencing food behaviors among Indian consumers and what those shifts may mean for the future of food and beverage innovation. The study is the latest in IFF’s GLP-1 global consumer insights following the company’s 2025 GLP-1 Consumer Opportunity Outlook.
Aug 25 · 05:30·Business Wire
Healthcare · Aerospace & defense
TOYOTA, Japan, August 25, 2026--SkyDrive Inc. ("SkyDrive"), a leading Japanese developer, manufacturer, and seller of compact eVTOL aircraft (*1), today announced that it will move forward with evaluating initial operational routes for the introduction of eVTOL medical logistics services in India, in partnership with Air India and Suzuki. This is part of the Memorandum of Understanding (MoU) that the three organizations signed in July 2026 to jointly study the feasibility of such operations.(*2)
Aug 25 · 05:06·Business Wire
Finance · Healthcare
Financial Highlights
For the six months Ended 30 June 2026
(HK$ million)
2026
2025
Change
Revenue
2,071.0
2,014.2
+2.8%
Gross Profit
731.0
677.0
+8.0%
Gross Profit margin
35.3%
33.6%
+1.7pp
Profit attributable to owners of the Company
175.2
157.0
+11.6%
Net profit margin
8.5%
7.8%
+0.7pp
Adjusted EBITDA
330.8
303.2
+9.1%
Earnings per share (HK cents)
16.79
15.05
+11.6%
HONG KONG, August 25, 2026 - Nissin Foods Company Limited (“Nissin Foods” or the “Company”, together with its subsidiaries, the “Group”; Stock code: 1475) has announced its interim results for the six months ended 30 June 2026 (“the reporting period”).
During the reporting period, the Group delivered solid profit growth, primarily driven by the resilient performance of its instant noodle business. Revenue increased by 2.8% year-on-year from HK$2,014.2 million in 2025 to HK$2,071.0 million in 2026, reflecting continued momentum in its core instant noodle business and broader store coverage in the Chinese Mainland. Gross profit increased by 8.0% year-on-year from HK$677.0 million to HK$731.0 million. Gross profit margin improved by 1.7 percentage points from 33.6% year-on-year to 35.3%, driven primarily by the continued expansion of the higher-margin core instant noodle business, the effective execution of raw material procurement strategies which helped mitigate the impact of raw material price volatility, and improved production efficiency.
Profit attributable to owners of the Company increased by 11.6% from HK$157.0 million in 2025 to HK$175.2 million in 2026, representing a net profit margin of 8.5% for the period. The Group’s basic earnings per share increased from 15.05 HK cents to 16.79 HK cents for the period. Adjusted EBITDA increased by 9.1% from HK$303.2 million to HK$330.8 million, representing the Adjusted EBITDA margin of 16.0% for the period, reflecting improved profitability at the operating level.
Review and Prospects of Different Business Regions
During the reporting period, revenue from the Hong Kong and other regions operations remained stable, increasing by 0.2% to HK$793.5 million (2025: HK$792.3 million), mainly attributable to the continued steady performance of the instant noodle business in the Hong Kong market and increased demand in other regions. Revenue from Chinese Mainland operations increased by 4.5% (in local currency: -0.1%) to HK$1,277.5 million (2025: HK$1,221.9 million), mainly attributable to the increased sales volume of instant noodles and the positive impact of foreign currency translation.
In Hong Kong, the instant noodles business delivered steady growth, driven by the resilient performance of flagship brands including Demae Iccho, Hokkaido Iccho, Cup Noodles and Cup Noodles BIG. To further enrich its instant noodle portfolio, the Group introduced a range of new SKUs, such as Nissin Stir Cup Noodles Seafood Flavour Instant Noodle and Nissin Viet Signature Beef Flavour Pho Noodle, and Demae Iccho Scallop and Salt Soup Flavour Instant Noodle. Continuing its IP promotion strategy, the collaboration with Japanese virtual singer “Hatsune Miku” also enhanced brand awareness and strengthened engagement with younger consumers.
As for non-noodle business, the Group expanded its premium frozen food portfolio with the launch of the “Doll Dim Sum” series. The Group also introduced a series of limited-edition products to capture seasonal demand and drive sales. Meanwhile, health-focused products, including the Hong Kong-made Nissin Granola and fresh-cut vegetable, continued to gain popularity, reflecting the Company’s commitment to health and wellness. In May 2026, the Group entered into a strategic partnership with Itochu Hong Kong Limited through a joint investment in Nissin Marketing and Sales (H.K.) Limited, which is expected to support the long-term development and competitiveness of the distribution business in Hong Kong and the Chinese Mainland.
In other regions, the Company continued to strengthen its presence in Vietnam with a focus on the youth segment to support instant noodles brand growth and market penetration. In Korea, Gaemi Food’s business performance was stable during the period, with the strategic focus on the expansion of its e-commerce business, enhancement of consumer engagement through “KEMY Mall”, and continuous product innovation. Gaemi Food continued to expand its presence in overseas markets including Hong Kong, Vietnam, and Taiwan. In Australia, ABC Pastry recorded stable performance supported by the launch of a range of new premium products. Australia Nissin also maintained solid business momentum during the period, driven by increased sales of instant noodles across nationwide supermarket chains and Asian supermarket channels through ongoing market development efforts and product innovation.
In the Chinese Mainland, the Group continued to advance its premiumisation strategy and strengthen its business foundation, while increasing instant noodle sales volume through broader market coverage and more diversified distribution channels. It upgraded select Cup Noodles products by increasing ingredient sizes to deliver an improved tasting experience for consumers. To further enrich its product line-up, the Company also introduced new products such as Nissin U.F.O. Singapore Chilli Crab Flavour, reinforcing its premium and innovative brand positioning. The Company continued its collaboration with the Japanese virtual singer "Hatsune Miku" to raise brand awareness and strengthen connections with consumers. As for the non-noodle business, the Company continued to strengthen its snacks, beverage and frozen food businesses through product innovation to address evolving consumer demand.
Mr. Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, “Despite continuing market volatility and geopolitical uncertainties, the Group delivered solid profit growth in the first half of 2026. This was supported by broader market coverage and the resulting increase in sales volume of our flagship brands. These results reflect the resilience of our business model and the effectiveness of our strategic initiatives. Our premiumisation strategy, diversified product portfolio and disciplined cost management have further strengthened our capability to navigate changing market conditions. As we continue to expand our presence in Hong Kong, the Chinese Mainland and overseas markets, we remain focused on delivering quality products and strengthening our brands. We are committed to achieving sustainable long-term growth and creating value for our shareholders.”
About Nissin Foods Company Limited
Nissin Foods Company Limited ("Nissin Foods”, together with its subsidiaries, the “Group”; Stock code: 1475) is a renowned food company in Hong Kong and the Chinese Mainland, with a diversified portfolio of well-known and highly popular brands, primarily focusing on the premium instant noodle segment. The Group officially established its presence in Hong Kong in 1984 and is the largest instant noodle company in Hong Kong. The Group primarily manufactures and sells instant noodles, high-quality frozen food products, including frozen dim sum and frozen noodles, and also sells and distributes other food and beverage products, including retort pouches, snacks, mineral water, sauce and vegetable products under its two core corporate brands, namely “NISSIN” and “DOLL (公仔)” together with a diversified portfolio of iconic household premium brands. The Group’s five flagship product brands, namely “Cup Noodles”, “Demae Iccho”, “Doll Instant Noodle”, “Doll Dim Sum” and “Fuku” are also among the most popular choices in their respective food product categories in Hong Kong. In the Chinese market, the Group has introduced technology innovation through the “ECO Cup” concept and primarily focuses its sales efforts in first- and second-tier cities. In addition, Nissin Foods operates business in other regions including Vietnam, Taiwan, Korea and Australia markets.
Nissin Foods is currently a constituent of five Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Composite SmallCap Index, Hang Seng Composite Industry Index - Consumer Staples, Hang Seng SCHK Consumption Index and Hang Seng SCHK Consumer Staples Index. Nissin Foods is eligible for trading under Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect. For more information, please visit www.nissingroup.com.hk.
Aug 25 · 04:45·ACN Newswire
Healthcare · Cybersecurity
National class action firm offering free case evaluations to individuals impacted by the Surgeons Choice Medical Center cybersecurity incident SOUTHFIELD, Mich., Aug. 24, 2026 -- Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims...
Aug 25 · 02:29·PR Newswire
Finance · Healthcare
NANJING, China, Aug. 24, 2026 -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that Opamtistomig (LBL-024), the Company’s proprietary PD-L1/4-1BB bispecific antibody, as a first-line treatment for locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), has completed its safety run‑in assessment and advanced to the expansion phase based on encouraging efficacy signals and a favorable safety profile.
Aug 25 · 02:25·GlobeNewswire
Finance · Healthcare
THE WOODLANDS, TX, Aug. 24, 2026 -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into a warrant inducement agreement with an investor (“Investor”) for the immediate exercise of certain outstanding warrants that the Company issued on July 15, 2026 (the “July 2026 Warrants”). Pursuant to a warrant inducement agreement, the Investor has agreed to exercise the outstanding July 2026 Warrants to purchase an aggregate of 857,462 shares of the Company’s common stock at the exercise price of $5.75. The resale of the shares of common stock issuable upon exercise of the July 2026 Warrants has been registered pursuant to an effective registration statement on Form S-3 (File No. 333-297760). The gross proceeds from the exercise of the warrants are expected to be approximately $4.9 million, prior to deducting financial advisory fees and estimated offering expenses.
Aug 25 · 01:06·GlobeNewswire
Healthcare · Biotech & pharma
SHANGHAI and HONG KONG, Aug. 24, 2026 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
Aug 25 · 00:30·PR Newswire
Healthcare
Vancouver, British Columbia--(August 24, 2026) - Apptly Health Technologies Corp. (CSE: APPT) (FSE: 4KL) (the "Company") is pleased to announce that it intends to complete a non-brokered private placement of up to 8,000,000 units of the Company (the "Units"), at a price of $0.125 per Unit, for aggregate gross proceeds of up to $1,000,000 (the "Offering"). The Company reserves the right to increase the size of the Offering in its sole discretion. The Offering is not subject to a...
Aug 25 · 00:00·Newsfile